BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. Cancer Genomics Proteomics. 2020;17:441-452. [PMID: 32859625 DOI: 10.21873/cgp.20203] [Cited by in Crossref: 38] [Cited by in F6Publishing: 60] [Article Influence: 38.0] [Reference Citation Analysis]
Number Citing Articles
1 Hempel L, Lapa C, Dierks A, Gaumann A, Scheiber J, Veloso de Oliveira J, Philipp P, Oyarzun Laura C, Wesarg S, Robert S, Hempel D. A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma. Ther Adv Med Oncol 2022;14:17588359221125096. [PMID: 36188486 DOI: 10.1177/17588359221125096] [Reference Citation Analysis]
2 Andersen LB, Mahler MSK, Andersen RF, Jensen LH, Raunkilde L. The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab. Cancers 2022;14:4598. [DOI: 10.3390/cancers14194598] [Reference Citation Analysis]
3 Yao X, Zhou Z, Xie Y, Huang Z, Lu S, Liu C, Wang J, Li X. Methodology established for the detection of circulating tumor DNA by hybridization capture. Biotechniques 2022. [PMID: 36065956 DOI: 10.2144/btn-2022-0029] [Reference Citation Analysis]
4 Zhu Q, Zhai S, Ge E, Li L, Jiao X, Xiong J, Zhu G, Xu Y, Qu J, Wang Z. Intrahepatic cholangiocarcinoma with gastric metastasis misdiagnosed as primary gastric cancer: A case report and literature review. Front Oncol 2022;12:997735. [DOI: 10.3389/fonc.2022.997735] [Reference Citation Analysis]
5 Li J, Chen Q, Guo L, Li J, Jin B, Wu X, Shi Y, Xu H, Zheng Y, Wang Y, Du S, Li Z, Lu X, Sang X, Mao Y. . CMAR 2022;Volume 14:2903-12. [DOI: 10.2147/cmar.s357000] [Reference Citation Analysis]
6 Okuno M, Mukai T, Iwata K, Watanabe N, Tanaka T, Iwasa T, Shimojo K, Ohashi Y, Takagi A, Ito Y, Tezuka R, Iwata S, Iwasa Y, Kochi T, Ogiso T, Hayashi H, Sugiyama A, Nishigaki Y, Tomita E. Evaluation of the Cell Block Method Using Overnight-Stored Bile for Malignant Biliary Stricture Diagnosis. Cancers (Basel) 2022;14:2701. [PMID: 35681681 DOI: 10.3390/cancers14112701] [Reference Citation Analysis]
7 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022:gutjnl-2022-327099. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Rogalska-Taranta M, Andersen JB. Involvement of Epigenomic Factors in Bile Duct Cancer. Semin Liver Dis 2022;42:202-11. [PMID: 35738258 DOI: 10.1055/s-0042-1748188] [Reference Citation Analysis]
9 Khosla D, Zaheer S, Gupta R, Madan R, Goyal S, Kumar N, Kapoor R. Role of intraluminal brachytherapy in palliation of biliary obstruction in cholangiocarcinoma: A brief review. World J Gastrointest Endosc 2022; 14(3): 106-112 [DOI: 10.4253/wjge.v14.i3.106] [Reference Citation Analysis]
10 Baj J, Bryliński Ł, Woliński F, Granat M, Kostelecka K, Duda P, Flieger J, Teresiński G, Buszewicz G, Furtak-Niczyporuk M, Portincasa P. Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know. Cancers (Basel) 2022;14:1493. [PMID: 35326644 DOI: 10.3390/cancers14061493] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zhang Y, Sun J, Song Y, Gao P, Wang X, Chen M, Li Y, Wu Z. Roles of fusion genes in digestive system cancers: dawn for cancer precision therapy. Crit Rev Oncol Hematol 2022;:103622. [PMID: 35124200 DOI: 10.1016/j.critrevonc.2022.103622] [Reference Citation Analysis]
12 Beri N. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncol 2022. [PMID: 35081733 DOI: 10.2217/fon-2021-1089] [Reference Citation Analysis]
13 Csoma SL, Bedekovics J, Veres G, Árokszállási A, András C, Méhes G, Mokánszki A. Circulating Cell-Free DNA-Based Comprehensive Molecular Analysis of Biliary Tract Cancers Using Next-Generation Sequencing. Cancers (Basel) 2022;14:233. [PMID: 35008396 DOI: 10.3390/cancers14010233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhou Y, Zhang Y, Gong H, Luo S, Cui Y. The Role of Exosomes and Their Applications in Cancer. Int J Mol Sci 2021;22:12204. [PMID: 34830085 DOI: 10.3390/ijms222212204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol 2021;:1-17. [PMID: 34669536 DOI: 10.1080/17474124.2021.1991313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Yu J, Mahipal A, Kim R. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. Onco Targets Ther 2021;14:5145-60. [PMID: 34720591 DOI: 10.2147/OTT.S272208] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
17 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Del Vecchio Blanco G, Mossa M, Troncone E, Argirò R, Anderloni A, Repici A, Paoluzi OA, Monteleone G. Tips and tricks for the diagnosis and management of biliary stenosis-state of the art review. World J Gastrointest Endosc 2021; 13(10): 473-490 [PMID: 34733408 DOI: 10.4253/wjge.v13.i10.473] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Hunter LA, Soares HP. Quality of Life and Symptom Management in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:5074. [PMID: 34680223 DOI: 10.3390/cancers13205074] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
20 Kamp EJCA, Peppelenbosch MP, Doukas M, Verheij J, Ponsioen CY, van Marion R, Bruno MJ, Koerkamp BG, Dinjens WNM, de Vries AC. Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity. Clin Transl Gastroenterol 2021;12:e00410. [PMID: 34608877 DOI: 10.14309/ctg.0000000000000410] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Repetto M, Crimini E, Giugliano F, Morganti S, Belli C, Curigliano G. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Rev Clin Pharmacol 2021;14:1233-52. [PMID: 34591728 DOI: 10.1080/17512433.2021.1947246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhang Z, Wang Z, Huang Y. A Bibliometric Analysis of 8,276 Publications During the Past 25 Years on Cholangiocarcinoma by Machine Learning. Front Oncol 2021;11:687904. [PMID: 34557406 DOI: 10.3389/fonc.2021.687904] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Zeng FL, Chen JF. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma. Technol Cancer Res Treat 2021;20:15330338211039952. [PMID: 34528830 DOI: 10.1177/15330338211039952] [Reference Citation Analysis]
24 Li Q, Che F, Wei Y, Jiang HY, Zhang Y, Song B. Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response. Expert Rev Gastroenterol Hepatol 2021;15:1267-79. [PMID: 34452581 DOI: 10.1080/17474124.2021.1974294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Bourien H, Lamarca A, McNamara MG, Hubner RA, Valle JW, Edeline J. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opin Investig Drugs 2021;30:975-83. [PMID: 34420429 DOI: 10.1080/13543784.2021.1964470] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Khairil Anwar NA, Mohd Nazri MN, Murtadha AH, Mohd Adzemi ER, Balakrishnan V, Mustaffa KMF, Tengku Din TADA, Yahya MM, Haron J, Mokshtar NF. Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochim Biophys Sin (Shanghai) 2021;53:961-78. [PMID: 34180502 DOI: 10.1093/abbs/gmab077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wintachai P, Lim JQ, Techasen A, Lert-Itthiporn W, Kongpetch S, Loilome W, Chindaprasirt J, Titapun A, Namwat N, Khuntikeo N, Jusakul A. Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma. Diagnostics (Basel) 2021;11:999. [PMID: 34070951 DOI: 10.3390/diagnostics11060999] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021;13:332-50. [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
29 Rizzo A. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina (Kaunas) 2021;57:458. [PMID: 34066684 DOI: 10.3390/medicina57050458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Kamp EJCA, Dinjens WNM, Doukas M, Bruno MJ, de Jonge PJF, Peppelenbosch MP, de Vries AC. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap Adv Gastroenterol 2021;14:17562848211002023. [PMID: 33948111 DOI: 10.1177/17562848211002023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Nara S, Esaki M, Ban D, Takamoto T, Mizui T, Shimada K. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:537-45. [PMID: 33793366 DOI: 10.1080/17474124.2021.1911645] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Rizzo A, Ricci AD, Brandi G. Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand? Expert Review of Precision Medicine and Drug Development 2021;6:217-24. [DOI: 10.1080/23808993.2021.1915126] [Reference Citation Analysis]
33 Rizzo A, Ricci AD, Frega G, Di Federico A, Brandi G. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert Rev Gastroenterol Hepatol 2021;15:567-74. [PMID: 33787429 DOI: 10.1080/17474124.2021.1911646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Rizzo A. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treat Res Commun 2021;27:100360. [PMID: 33799005 DOI: 10.1016/j.ctarc.2021.100360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun 2021;27:100356. [PMID: 33799004 DOI: 10.1016/j.ctarc.2021.100356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
36 Han Y, Zhang H, Zhou Z, Liu R, Liu D, Bai M, Fan Q, Li J, Zhu K, Li H, Ning T, Ying G, Ba Y. Serum microRNAs as Biomarkers for the Noninvasive Early Diagnosis of Biliary Tract Cancer. Int J Gen Med 2021;14:1185-95. [PMID: 33833559 DOI: 10.2147/IJGM.S297371] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Boilève A, Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs 2021;30:401-9. [PMID: 33641556 DOI: 10.1080/13543784.2021.1896703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sutherland M, Ahmed O, Zaidi A, Ahmed S. Current progress in systemic therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci 2021. [PMID: 33735541 DOI: 10.1002/jhbp.939] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun 2021;27:100354. [PMID: 33756174 DOI: 10.1016/j.ctarc.2021.100354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
40 Rizzo A, Brandi G. TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks. Cancer Treat Res Commun 2021;27:100351. [PMID: 33752169 DOI: 10.1016/j.ctarc.2021.100351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
41 DiPeri TP, Javle MM, Meric-Bernstam F. Next generation sequencing for biliary tract cancers. Expert Rev Gastroenterol Hepatol 2021;15:471-4. [PMID: 33641586 DOI: 10.1080/17474124.2021.1896967] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
42 Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:343-50. [PMID: 33645367 DOI: 10.1080/13543784.2021.1897102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
43 Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics 2021;11:4585-98. [PMID: 33754015 DOI: 10.7150/thno.56539] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
44 Rizzo A, Brandi G. Novel Targeted Therapies for Advanced Cholangiocarcinoma. Medicina (Kaunas) 2021;57:212. [PMID: 33652960 DOI: 10.3390/medicina57030212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
46 Wu T, Jiang X, Zhang X, Wu B, Xu B, Liu X, Zheng L, Wang Y. Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors. Cancer Control 2021;28:1073274821989314. [PMID: 33618536 DOI: 10.1177/1073274821989314] [Reference Citation Analysis]
47 Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology & Hepatology 2021;15:547-54. [DOI: 10.1080/17474124.2021.1890031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
48 Rizzo A, Ricci AD, Brandi G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun 2021;27:100337. [PMID: 33611090 DOI: 10.1016/j.ctarc.2021.100337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
49 Rizzo A, Brandi G. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treat Res Commun 2021;27:100334. [PMID: 33592563 DOI: 10.1016/j.ctarc.2021.100334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
51 Onoyama T, Hamamoto W, Sakamoto Y, Kawahara S, Yamashita T, Koda H, Kawata S, Takeda Y, Matsumoto K, Isomoto H. Peroral Cholangioscopy-Guided Forceps Mapping Biopsy for Evaluation of the Lateral Extension of Biliary Tract Cancer. J Clin Med 2021;10:597. [PMID: 33562535 DOI: 10.3390/jcm10040597] [Reference Citation Analysis]
52 Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun 2021;27:100328. [PMID: 33549983 DOI: 10.1016/j.ctarc.2021.100328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
53 Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel) 2021;13:558. [PMID: 33535621 DOI: 10.3390/cancers13030558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 66] [Article Influence: 25.0] [Reference Citation Analysis]
54 Beaulieu C, Lui A, Yusuf D, Abdelaziz Z, Randolph B, Batuyong E, Ghosh S, Bathe OF, Tam V, Spratlin JL. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada. Curr Oncol 2021;28:417-27. [PMID: 33450805 DOI: 10.3390/curroncol28010044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 13] [Cited by in F6Publishing: 55] [Article Influence: 13.0] [Reference Citation Analysis]
56 Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Cancer Control 2020;27:1073274820983013. [PMID: 33356500 DOI: 10.1177/1073274820983013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Di Federico A, Rizzo A, Ricci AD, Frega G, Palloni A, Tavolari S, Brandi G. Nivolumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:325-32. [PMID: 33307866 DOI: 10.1080/13543784.2021.1863946] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
58 Zhao J, Zhang W, Zhang J, Chen YT, Ma WJ, Liu SY, Li FY, Song B. Independent Risk Factors of Early Recurrence After Curative Resection for Perihilar Cholangiocarcinoma: Adjuvant Chemotherapy May Be Beneficial in Early Recurrence Subgroup. Cancer Manag Res 2020;12:13111-23. [PMID: 33376403 DOI: 10.2147/CMAR.S289094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
59 Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterology & Hepatology 2021;15:483-5. [DOI: 10.1080/17474124.2021.1864325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
60 García P, Lamarca A, Díaz J, Carrera E, Roa JC, On Behalf Of The European-Latin American Escalon Consortium. Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients. Cancers (Basel) 2020;12:E3670. [PMID: 33297469 DOI: 10.3390/cancers12123670] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
61 Rizzo A, Ricci AD, Bonucci C, Tober N, Palloni A, Frega G, Brandi G. Experimental HER2- targeted therapies for biliary tract cancer. Expert Opin Investig Drugs 2021;30:389-99. [PMID: 33218269 DOI: 10.1080/13543784.2021.1854724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
62 Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opinion on Investigational Drugs 2021;30:317-24. [DOI: 10.1080/13543784.2021.1837774] [Cited by in Crossref: 23] [Cited by in F6Publishing: 44] [Article Influence: 11.5] [Reference Citation Analysis]